@MondayNightIBD OnDemand: Addressing the Cases That Challenge Your Practice

1.50 ABIM MOC
1.50 CME
90 MINS
$0 FEE
SAVE
gastro

Overview

Activity Dates

Release: June 26, 2020
Expiration: June 26, 2021


Target Audience

Gastroenterologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists


Support Statement

Supported by educational grants from AbbVie Inc., Takeda Pharmaceuticals U.S.A., Inc. and UCB, Inc


Statement of Need

Gastroenterologists are trailblazers in health care social media, and @MondayNightIBD has harnessed that energy to establish gastroenterologists as not just social media influencers but as clinical practice influencers as well. @MondayNightIBD is not just a weekly social media conversation – it is an international platform that is moving the field forward by crowdsourcing the expertise of leading inflammatory bowel disease (IBD) experts, community clinicians, and patients to meet the many challenges of IBD.

CME Outfitters has partnered with @MondayNightIBD to bring its founder Dr. Aline Charabaty's hugely successful endeavor to learners via an on demand webcast where a panel of experts discuss a series of patient cases with the goal of helping clinicians better understand, share, and implement optimal management strategies for IBD.


Learning Objective

CME/CE:
At the end of this CME/CE activity, participants should be able to:

  1. Apply efficacy, safety, and comparative effectiveness data for existing and emerging therapies to optimize therapy selection for patients with IBD.
  2. Identify appropriate treatment strategies for special populations with IBD such as pregnant/lactating women, the elderly, and patients with Clostridioides difficile infection (CDI).
  3. Develop strategies, such as disease monitoring, therapeutic drug monitoring (TDM), shared decision-making (SDM), and patient education, to achieve optimal patient outcomes.

CNE/CPE:
The following learning objectives pertain only to those requesting CNE or CPE credit:

  1. Explain efficacy, safety, and comparative effectiveness data for existing and emerging therapies to optimize therapy selection for patients with IBD.
  2. Identify appropriate treatment strategies for special populations with IBD such as pregnant/lactating women, the elderly, and patients with CDI.
  3. Describe strategies, such as disease monitoring, TDM, SDM, and patient education, to achieve optimal patient outcomes.

Faculty

Aline Charabaty, MD, AGAF (Chair) 
Clinical Director of Gastroenterology
Director, Inflammatory Bowel Disease Center
Sibley Memorial Hospital
Assistant Professor of Medicine
Johns Hopkins School of Medicine
Washington, DC

Uma Mahadevan, MD, AGAF, FACG 
Professor of Clinical Medicine
Co-Director
UCSF Center for Colitis and Crohn's Disease
Director of Advanced IBD Fellowship
Chief, GI Faculty Practice
University of California, San Francisco
San Francisco, CA

Miguel Regueiro, MD, AGAF, FACG, FACP 
Professor and Chair
Department of Gastroenterology, Hepatology & Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Cleveland Clinic
Cleveland, OH


Credit Offered

AMA, ACPE, CBRN, ABIM MOC
Activity qualifies for MIPS

Credit amount: 1.5


Credit Statements

CME:
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Learning Formats:
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

CNE:
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.


Disclosure

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Charabaty reports that she serves on the advisory committee for Janssen Pharmaceuticals, Inc. She is a consultant for AbbVie Inc.; Janssen Pharmaceuticals, Inc; and Pfizer Inc.

Dr. Mahadevan reports that she receives grants from Celgene Corporation; Genentech, Inc.; and Pfizer Inc. She is a consultant for AbbVie Inc.; Bristol Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.; He is on advisory boards and a consultant for AbbVie Inc.; Allergan; Amgen Inc; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).